Promising Epigenetic Biomarkers for the Early Detection of Colorectal Cancer: A Systematic Review
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In CRC, screening compliance is decreased due to the experienced discomfort associated with colonoscopy, although this method is the gold standard in terms of sensitivity and specificity. Promoter DNA methylation (hypomethylation or hypermethylation) has been linked to all CRC stages. Study objectives: to systematically review the current knowledge on approved biomarkers, reveal new potential ones, and inspect tactics that can improve performance. This research was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; the risk of bias was evaluated using the revised Quality Assessment of Diagnostic Accuracy Studies criteria (QUADAS-2). The Web of Science® Core Collection, MEDLINE® and Scopus® databases were searched for original articles published in peer-reviewed journals with the specific keywords “colorectal cancer”, “early detection”, “early-stage colorectal cancer”, “epigenetics”, “biomarkers”, “DNA methylation biomarkers”, “stool or blood or tissue or biopsy”, “NDRG4”, “BMP3”, “SEPT9”, and “SDC2”. Based on eligibility criteria, 74 articles were accepted for analysis. mSDC2 and mSEPT9 were frequently assessed in studies, alone or together as part of the ColoDefense panel test—the latter with the greatest performance. mBMP3 may not be an appropriate marker for detecting CRC. A panel of five methylated binding sites of the CTCF gene holds the promise for early-stage specific detection of CRC. CRC screening compliance and accuracy can be enhanced by employing a stool mt-DNA methylation test.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Alvandi, E., Wong, W. K. M., Joglekar, M. V., Spring, K. J., & Hardikar, A. A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02529-4 · Cited by 101
“Fecal SCFA could be considered as a potential non-invasive biomarker to be measured in combination with or as an alternative to the commonly used noninvasive and current CRC screening methods [74, 77], to improve specificity and sensitivity of current screening, as well as for potential early detection of CRA.”
MethodCurrent Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics
Beniwal, S., Lamo, P., Kaushik, A., Lorenzo-Villegas, D., Liu, Y., & MohanaSundaram, A. (2023) · Biosensors · doi:10.3390/bios13100926 · Cited by 60
“The incorporation of these biomarkers into routine clinical practice has the potential to revolutionize CRC management, fostering improved patient outcomes, refined treatment decisions, and a more targeted approach to combating this complex disease [49].”
BackgroundGăină, M.-A., Szalontay, A. S., Ștefănescu, G., Bălan, G. G., Ghiciuc, C. M., Boloș, A., Găină, A.-M., & Ștefănescu, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061670 · Cited by 44
“However, other research directions pursue raising sensitivity and specificity of currently available alternative screening procedures, such as the imagistic analysis [8], epigenetic faecal biomarkers [9], urine, and exhaled breath or blood-based biomarkers [10].”
Background
Metadata
- Authors
- Anghel, S. A., Ioniță-Mîndrican, C.-B., Luca, I., & Pop, A. L.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-10-02
- Volume
- 13
- Issue
- 19
- Pages
- 4965
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3202133019
- Cited by
- 38
- References
- 4
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promising Epigenetic Biomarkers for the Early Detection of Colorectal Cancer: A Systematic Review. https://app.cochat.ai/papers/10.3390/cancers13194965
- The paper
- Anghel, S. A., Ioniță-Mîndrican, C.-B., Luca, I., & Pop, A. L. (2021). Promising Epigenetic Biomarkers for the Early Detection of Colorectal Cancer: A Systematic Review. Cancers. https://doi.org/10.3390/cancers13194965
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.